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9The direct cell labeling techniques
Cells(for cancer issues 
dendritic cells , T cells 
cancer immunotherapy 
and cancer properties  
MSCs )   are incubated 
with an MRI contrast 
agent in vitro and prior to 
transplantation , with a 
transfection agent such as 
PLL or lipofectamine
Cancer tracking
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The direct cell labeling 
techniques
Endogen exogen
Entrance of CA Pinocytosis
Phagocytosis
With sonication
electroporation
CA ( MNP , 
paramagnetic , Gd , 
SPIONs 
superparamagnetic 
iron oxidate np)to 
macrophage
The way of labeling Targeting the cell surface 
receptors with antibody 
conjugated MRI CA or
targeting phagocytic nature 
of endogenous cell 
population 
Like endogen 
limitation Yes for the difficulty 
of isolating the neural 
stem cell because 
they are sub 
ventricular zone
It can’t distinguish 
between live and death 
cells 
1:the differences T1and 
T2 of CA in live and death 
cells 
2:effect of PH which 
usually with death cells
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The indirect cell labeling techniques
Cells transfected 
with transfection 
agents or transduced 
with viral vectors to 
express an MRI 
reporter gene.
A Reporter gene is a 
gene that can fused to a 
gene of interest or 
cloned after that 
expression of it can 
create a peptide, protein 
Nano structure receptor 
or enzymatic activation 
to generate an MRI 
contrast
Cancer tracking
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The indirect cell labeling techniques
Advantage 
of the 
indirect 
technique
s 
Use genetically 
engineering 
Engineered cells 
proliferate to 
generate 
daughter cells
MRI signal is not 
diluted
Live labeled cells 
distinguished 
from dead cells
The reporter gene 
is expressed only 
in live cells and 
switched off in 
dead cells
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15
Examples of 
MRI 
reporter 
gene 
systems
Iron _binding 
receptor 
transferrin (that 
require T2/T2* 
MRI contrast 
agent )
The iron storage  
protein ferritin (that 
require T2/T2* MRI 
contrast agent )
The_ β
galactosidase which 
hydrolysis of  β _D 
_ galactosidases(the 
require T1 MRI 
contrast agent like 
Gd  )
Reporter genes 
which use CEST 
contrast generation 
mechanism such as 
:LRP(lysine rich 
protein)or HSV1
The indirect cell labeling techniques
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-use of imaging agents with 
unfavorable pharmacokinetic 
profile lead to a delayed MRI 
signal and then result in false 
negative low sensitivity of 
reporter genes by biological 
function lead to low  detection
_developed reporter gen in 
bacterial origins non human 
origins _usually reporter genes 
are immunogenic 
Limitation of indirect cell labeling 
techniques:
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The encapsulation cell labeling Technique
_Use of biomaterials : such as alginate capsules 
to protect therapeutic cells from immune cells 
and permit the diffusion of small molecular 
weight such as water and nutrients
_ polycations such as :PLL(poly _L _ lysine)to 
control pore sizes
-Therapeutic cells and MRI agents  are 
encapsulated together in vitro prior to 
transplantation 
Cancer tracking
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The encapsulation cell labeling Technique
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Statistic in cancer tracking between 2000-2017 years
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PET- CT(positron emission computed tomography)
• Pet CT is a type of nuclear medicine imaging
• Nuclear medicine is a branch of medical imaging
that uses small amounts of radioactive material to 
detect severity or treat diseases include many type 
of cancers heart diseases , neurological disorder 
endocrine and gastrointestinal 
• Because nuclear medicine procedure able pinpoint 
molecular activity within the body 
Cancer tracking
https://image.slidesharecdn.com/medicalimaging-130804074029-phpapp01/95/medical-imaging-
overview-21-638.jpg?cb=1375602411
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the principals of pet CT  imaging
• PET imaging uses radiopharmaceuticals (or radiotracers like 
DG( deoxy glucose )and … labeled with positron emitting 
radioisotopes such as 11C, 13N, 15O, and 18F,which are 
produced in a cyclotron which are produced in a radioisotope 
generator.
• the positron annihilates and generates 2 annihilation photons 
(each with an energy of 511 k eV),which travel in opposite 
directions.
• PET scanners are equipped with coincidence electronics to 
detect these pairs of photons as they hit opposing detectors 
Cancer tracking
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Radiotracer 
of PET CT
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the mechanism of radiotracers like FDG
• Radiotracers in PET/CT allows to quantify the metabolic activity 
of a tumor (like glycolysis) and become a reference tool in 
oncology for the tissue staging ,radiotherapy planning and 
monitoring  response in many cancers.
• In 18 F- fluorodeoxyglucose (18F-FDG) is transported into cells in 
parallel with glucose and is phosphorylated with hexokinase to 
F_deoxyglycose-6-phosphate because lack of a hydroxyl group at 
the 2 position , it’s prevented from being a substrate of enzymes 
farther down the glycolytic pathway
• FDG_6_phosphate trapped within the cancer cells
• Because of isotope like F we can detect them with PET CT
Cancer tracking
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FDG uptake mechanism 32
https://www.researchgate.net/profile/Artem_Lebedev/publication/259010016/figure/fig2/AS:267481113690123@
1440783875152/Figure-10-10-Proposed-mechanism-for-the-cellular-accumulation-of-18FFDG.png
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which cancer we can use  FDG? 
 FDG-PET include lymphoma, head and neck cancer,
lung, colorectal cancer, breast cancer, esophageal 
cancer, melanoma, cervical cancer, thyroid cancer, 
and pancreatic cancer are “hot”
 prostate cancer, neuroendocrine cancer,
and well differentiated hepatocellular carcinoma, are 
often “cold” which limits the utility of FDG-PET 
Cancer tracking
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30-deoxy-30-18F-fluorothymidine (FLT)
• It uses for imaging cell proliferation 
• Initial efforts focused on synthesizing analogs of 
thymidine, because thymidine is used by
proliferating cells for DNA synthesis during the S-phase
of the cell cycle but, unlike other nucleosides, is not 
incorporated into RNA 
• After  injection, FLT enters the cell by  nucleoside 
transporters and is trapped in the cytosol through 
phosphorylation
• Because FLT lacks a hydroxyl group at the 3′position, it
is not incorporated into DNA , and its accumulation
serves as a measure of cellular proliferation 
Cancer tracking
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The thymidine analog (1-[20-deoxy-20-18Ffluoro-beta-D_arabinofuranosyl]thymine) (FMAU) 
• proliferation imaging probes
• for studying bone metastases and genitourinary 
malignancies 
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PET radiotracers have been developed to image hypoxia
2-nitroimidazoles, such as:
• 18F_fluoromisonidazole 
(FMISO)(research)
• 18F-fluoroetanidazole 
(FETA) 
In solid tumors, hypoxia is associated 
with restrained proliferation, 
differentiation, apoptosis, and necrosis 
nucleoside conjugates, such as
• 18F-fluoroazomycin 
arabinoside (FAZA)
• 64Cu-diacetyl-bis(N4-
methylthiosemicarbazone) 
(Cu-ATSM) 
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36 PET radiotracers have been developed to image hypoxia
All of these agents undergo 
intracellular trapping at a rate
inversely proportional to intracellular 
oxygen concentration 
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Imaging Apoptosis
 the detection of apoptosis can potentially be used to provide an
early indication of the success of therapy(in radiotherapy)
 phosphatidylserine residues that normally reside on the intracellular
membrane surface but that are translocated to the extracellular surface during apoptosis
 99mTc-annexin V is able to image apoptosis in vivo and to
predict patient outcome after chemotherapy or radiation
therapy. 
 a radiolabeled protein with affinity to phosphatidylserine 
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The second class of imaging agents 
targets caspases 
 18F-ICMT-11 (a caspase-3- specific small molecule PET tracer based on the caspase inhibitor 
statin)
 18F-CP18 (a pentapeptide-based PET tracer that is a substrate of caspase-3)
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A third class of imaging agents
It  detect plasma membrane depolarization 
the most notable of these imaging agents is the PET tracer 18F-ML-10 
39
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Immunology , 
bioluminescence and 
optical fluorescence imaging 
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Cancer tracking with immunology
The imaging modalities applied for T cell tracking in 
both preclinical and clinical studies include:
optical fluorescence/bioluminescence
imaging , computed tomography (CT), magnetic 
resonance imaging (MRI), positron emission 
tomography (PET)
Cancer tracking
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Cytotoxic T lymphocytes and cell labeling methods
 However, in immunotherapy, cytotoxic T cells can be 
manipulated to recognize tumor-specific antigens When 
infused into a patient, the engineered T cells actively 
attack and destroy the tumors displaying these antigens 
 There are two major principles in labeling the T cells for in 
vivo cell tracking: 
direct and indirect labeling 
Cancer tracking
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Cytotoxic T lymphocytes and cell labeling methods
Direct labeling
 generally requires isolation and ex vivo
expansion of the T cells from the subject, followed by
labeling with a proper imaging probe in vitro and injection of 
these cells into the subject
indirect labeling
 involves genetic engineering of the T cells by transfecting
them with a reporter gene that encodes an enzyme or 
transporter, which can utilize the designated imaging probe 
as a substrate and allow for visualization and tracking of 
these T cells over time 
Cancer tracking
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Tracking T cells by optical fluorescence and bioluminescence imaging
 In optical fluorescence imaging, T cells are labeled by fluorophores, 
fluorescent proteins, or quantum dots 
 The fluorophores are usually near infrared (NIR) fluorescent dyes, 
such as indocyanine green 
 labeled cells could be detected by flow cytometry
 the labeled CTLs and the tumor cells could be detected by confocal 
intravital microscopy 
 The optical fluorescence imaging with fluorophores usually adopts 
a direct labeling strategy, while imaging with fluorescent proteins
involves an indirect method 
 Quantum dots (QDs) are a 
class of semiconductor 
nanocrystals (2-6 nm in 
size) that have broad 
excitation spectra
 Direct labeling methods
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Tracking T cells by optical fluorescence and bioluminescence imaging
Indirect labeling methods
 Bioluminescence optical imaging is in principle distinct from the 
fluorescence imaging and involves an indirect labeling strategy. 
 Indirect labeling by fluorescent proteins. 
 Fluorescent proteins, such as green fluorescent protein (GFP) 
and red fluorescent protein (RFP), are also used to tag the T 
cells 
 A DNA construct carrying a coding sequence for GFP or RFP
is introduced into the cell 
 It has become a powerful means to probe the mechanisms for 
biological processes in vitro and in preclinical studies. 
Cancer tracking
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Tracking T cells by optical fluorescence and bioluminescence imaging
Indirect labeling methods
Indirect labeling by bioluminescent agents:
 a luciferase enzyme is expressed in the cell; when its substrate 
luciferin is introduced, luciferase can catalyze the oxidation of 
luciferin in the presence of ATP and oxygen
 The reaction emits photons and only living cells can produce signals
 produced a transgenic bioluminescence mouse model from which 
they isolated the T cells that constantly expressed luciferase 
 The BLI results clearly showed these adoptively transferred T cells 
homed to the antigen-positive tumors.
Cancer tracking
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